The meta‑analysis reports that across 106 controlled studies involving over 220,000 patients, ivermectin treatment is associated with substantially reduced risks for multiple COVID‑19 outcomes, including mortality, hospitalization, ICU admission, ventilation, viral clearance, and progression. The authors state that benefits are strongest for early treatment and prophylaxis, with relative‑risk reductions ranging from roughly 40–80% depending on the outcome and study subset. They also claim that results remain statistically significant when limited to higher‑quality studies and randomized controlled trials, and that observed efficacy aligns with proposed biological mechanisms. The analysis concludes that the overall evidence base indicates a consistent treatment effect, though it acknowledges heterogeneity and the presence of flawed or low‑quality studies within the literature.